Skip to content

Clinical Geriatric Psychopharmacology

Spend $50 to get a free DVD!

ISBN-10: 0683300210

ISBN-13: 9780683300215

Edition: 3rd 1998 (Revised)

Authors: Carl Salzman

List price: $125.00
Blue ribbon 30 day, 100% satisfaction guarantee!
Out of stock
what's this?
Rush Rewards U
Members Receive:
Carrot Coin icon
XP icon
You have reached 400 XP and carrot coins. That is the daily max!


Thoroughly updated for its Fourth Edition, this volume is the most authoritative clinical reference on the pharmacological treatment of psychiatric disorders in elderly patients.This edition provides complete information on new psychotropic drugs, new uses for established drugs, and clinically relevant advances in the neurosciences. Also, four new chapters cover genes, pharmacokinetics, and their impact on prescribing; new cognition enhancing strategies and drugs; late life depression and physical illness; and also depression and cardiac disease in late life.The book offers detailed guidelines including drug names, dosages, and prescribing recommendations for pharmacological treatment of…    
Customers also bought

Book details

List price: $125.00
Edition: 3rd
Copyright year: 1998
Publisher: Lippincott Williams & Wilkins
Binding: Hardcover
Pages: 614
Size: 7.50" wide x 10.50" long x 1.50" tall
Weight: 2.794
Language: English

Prefacep. vii
Contributorsp. ix
Older Americans and Mental Illnessp. 3
Characteristics of U.S. Elderlyp. 3
Benefits of Treatmentp. 6
Rates of Mental Disordersp. 6
Problems in the Use of Psychotropic Drugsp. 11
Treatment Settingsp. 13
Clinician Misperceptions in Use of Psychotropic Medicationsp. 15
Drug Prescribing, Adverse Reactions, and Compliance in Elderly Patientsp. 23
Prescription-Drug Use Concernsp. 23
Over-the-Counter Medication Concernsp. 25
Prevalence of Psychotropic Drug Usep. 26
Psychotropic Prescribing Practices in Selected Settingsp. 26
Approaches to Improving Prescription Practicesp. 28
Common Side Effects of Psychotropic Drug Usep. 32
Ageism, Polypharmacy, and Adverse Drug Reactionsp. 35
Nutritional Status and Drug Effectsp. 37
Compliancep. 37
Conclusionp. 42
The Cost of Psychotropic Drug Use for the Elderlyp. 49
2003 Medicare Prescription Drug Legislationp. 51
Rise in Prescription Drug Costsp. 52
Psychotropic Drug Utilizationp. 55
Psychotropic Drug Costs and Compromised Patientsp. 56
Conclusionsp. 58
The Aging Process and Response to Psychotropic Drugs
Neurotransmission in the Aging Central Nervous Systemp. 63
The Neurotransmission Processp. 64
Effect of Age on Neurotransmittersp. 66
Effect of Psychotropic Drugs on Neurotransmissionp. 76
Age-Related Central Nervous System Alterations in Receptor Sensitivity and Psychotropic Drug Effectsp. 77
Kinetics and Dynamics of Psychotropic Drugs in the Elderlyp. 87
Basic Pharmacokinetic Principles and the Aging Processp. 88
Pharmacokinetics of Specific Drug Groupsp. 96
Using Pharmacokinetic Information in Prescribing Psychotropic Drugsp. 105
Commentp. 106
Geriatric Agitation and Behavior Disorders
Diagnosis of Late-Life Disordered Behavior, Agitation, and Psychosisp. 117
Characteristics of Disordered Behaviorp. 117
Causes of Behavioral Symptomsp. 117
Conclusionp. 124
Treatment of Late-Life Disordered Behavior, Agitation, and Psychosisp. 129
General Principles for Antipsychotic Treatmentp. 129
Side Effects of Antipsychoticsp. 133
Choice of Antipsychoticsp. 143
Treatment of Agitation with Non-Antipsychotic Drugsp. 160
Use of Antipsychotics in Difficult Clinical Situationsp. 170
Affective Disorders
Diagnosis of Late-Life Depressionp. 199
Epidemiologyp. 199
Diagnosis as Processp. 200
Onset of Depressionp. 206
Major Depressive Episodep. 206
Nonmajor Depressive Disordersp. 210
Neuropsychiatry of Late-Life Depressionp. 212
Consequences of Depressionp. 217
Treatment of Depression with Tricyclic Antidepressants, MAOIs, and Psychostimulantsp. 233
Tricyclic Antidepressantsp. 233
Monoamine Oxidase Inhibitorsp. 267
Psychostimulantsp. 275
Treatment of Psychotic Depressionp. 277
Augmenting Strategiesp. 278
Treatment of Depression with New and Atypical Antidepressantsp. 305
Selective Serotonin Reuptake Inhibitorsp. 305
Other Atypical Antidepressantsp. 316
Treatment Durationp. 321
Treatment of Late-Life Depression Associated with Medical Illnessp. 335
Comorbidity of Depression with Medical Illnessp. 335
Cardiovascular Diseasep. 336
Hypertensionp. 339
Strokep. 339
Parkinson's Disease and Depressionp. 340
Cancerp. 342
Treatment of Depression in Dementiap. 344
Diagnosis and Treatment of Late-Life Bipolar Disorderp. 353
Epidemiologyp. 353
Clinical Presentation and Diagnosisp. 353
Course of Illnessp. 354
Etiologyp. 355
General Treatment Principlesp. 356
Acute Treatment of Maniap. 356
Treatment with Lithiump. 358
Treatment with Anticonvulsantsp. 364
Treatment of Mania with Antipsychoticsp. 367
Treatment with other Agentsp. 369
Electroconvulsive Therapyp. 369
Electroconvulsive Therapy in Late-Life Depressionp. 385
Indications for ECTp. 386
Efficacyp. 387
Medical Complications and Relative Contraindicationsp. 397
Cognitive Side Effectsp. 397
ECT for Depressed Patients with Neurologic Disordersp. 403
Response Prediction, Maintenance Treatment, and Late-Life Depressionp. 423
Clinical Correlates of Treatment Response and Predictionp. 423
Neurobiologic Correlates of Outcome and Predictionp. 425
Prediction of Relapse, Recurrence, and Remissionp. 427
Maintenance Treatmentp. 428
Conclusionsp. 429
Anxiety and Related Disorders (Panic, Obsessive Compulsive, Phobias)
Diagnosis of Anxiety and Anxiety-Related Disordersp. 437
Epidemiologyp. 437
Characteristics of Late-Life Anxietyp. 438
Differential Diagnosisp. 438
Diagnostic Evaluationp. 442
Neurobiologic Mechanisms of Anxietyp. 443
Panic Anxiety, Obsessive-Compulsive Disorders, Phobiasp. 444
Conclusionsp. 446
Treatment of Anxiety and Anxiety-Related Disordersp. 449
Acute Anxiety and Generalized Anxiety Disorderp. 449
Anxiety Spectrum Disordersp. 465
Sleep Disorders
The Impact of Age on Sleep and Sleep Disordersp. 483
Neurobiologic and Chronobiologic of Normal Sleepp. 483
Normal Age-Related Changes in Sleep and Wakefulnessp. 488
Napping Behaviors and Excessive Daytime Sleepinessp. 489
Formal Evaluation of Sleep Disordersp. 490
Types of Sleep-Wake Disordersp. 493
Special Issues and Sleep-Wake Patterns in The Elderlyp. 499
Dementia and Sleepp. 501
Conclusionp. 501
Treatment of Insomnia in the Elderlyp. 513
Insomnia Complaints and Use of Medicationsp. 515
Treating Insomnia in Later Lifep. 515
Pharmacologic Treatment of Late-Life Insomniap. 520
Principles/Recommendations for Treatmentp. 521
Behavioral Treatments of Chronic Primary Insomniap. 529
Conclusionp. 529
Dementia and Memory Disorders
Neurobiology of Alzheimer's Diseasep. 543
Neuropathologyp. 543
Constituents of Senile Plaques and Neurofibrillary Tanglesp. 547
Biology of Amyloidp. 548
Neurotransmitters and Their Receptorsp. 550
Energy Metabolismp. 556
Cell Membranesp. 557
Inflammation and Immune Mechanismsp. 560
Infectious Agents and Toxinsp. 561
Mechanisms of Cell Deathp. 563
Genetics of Alzheimer's Diseasep. 563
Etiologic Modelp. 568
Conclusions and Future Directionsp. 572
Treatment of Dementiap. 595
Treatment Implications of Alzheimer's Disease Pathologyp. 595
Cholinergic Restitutive Therapiesp. 596
Other Neurotransmitter-Based Approachesp. 603
Nonneurotransmitter Treatment Strategiesp. 605
Nootropicsp. 608
Combination Treatmentsp. 608
Current Clinical Considerationsp. 608
Prescribing Informationp. 625
Enzyme Metabolism and Drug Interactionp. 631
Drug Interactions with Psychotropic Medicationsp. 643
Indexp. 677
Table of Contents provided by Rittenhouse. All Rights Reserved.